Journal
Infection & Chemotherapy
Publication Date
3-1-2023
Volume
55
Issue
1
First Page
50
Last Page
58
Document Type
Open Access Publication
DOI
10.3947/ic.2022.0127
Rights and Permissions
Sarojvisut P, Apisarnthanarak A, Jantarathaneewat K, Sathitakorn O, Pienthong T, Mingmalairak C, Warren DK, Weber DJ. An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand. Infect Chemother. 2023 Mar;55(1):50-58. doi: 10.3947/ic.2022.0127. Epub 2022 Dec 12. Copyright © 2023 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Recommended Citation
Sarojvisut, Phahol; Apisarnthanarak, Anucha; Jantarathaneewat, Kittiya; Sathitakorn, Ornnicha; Pienthong, Thanus; Mingmalairak, Chatchai; Warren, David K.; and Weber, David J., "An open label randomized controlled trial of ivermectin plus favipiravir-based standard of care versus favipiravir-based standard of care for treatment of moderate COVID-19 in Thailand." Infection & Chemotherapy. 55, 1. 50 - 58. (2023).
https://digitalcommons.wustl.edu/oa_4/1886
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
